Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward V Loftus

Showing results (291-300 of 471) with videos related to

Pageof 48
Sort By:
Crohn'S & Colitis 360|August 28, 2023
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE StudiesWilliam J Sandborn, Jingjing Chen, Krisztina Kisfalvi, et al.
Gastroenterology|December 31, 2003
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patientsJean-Frederic Colombel, Edward V Loftus, William J Tremaine, et al.
Inflammatory Bowel Diseases|October 19, 2016
Increased Rates of Clostridium difficile Infection and Poor Outcomes in Patients with IBD with CytomegalovirusJeffrey D McCurdy, Felicity T Enders, Sahil Khanna, et al.
The American Journal of Gastroenterology|May 5, 2026
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE StudyEdward V Loftus, Namita Joshi, Bruce E Sands, et al.
Gut|December 15, 2016
Development of a Microscopic Colitis Disease Activity Index: a prospective cohort studyThomas G Cotter, Moritz Binder, Edward V Loftus, et al.
The American Journal of Gastroenterology|July 24, 2002
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitisElena Ricart, William R Taylor, Edward V Loftus, et al.
Journal of Crohn'S & Colitis|October 22, 2022
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's DiseaseRishika Chugh, Manuel B Braga-Neto, Thomas W Fredrick, et al.
The American Journal of Gastroenterology|October 16, 2008
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trialEdward V Loftus, Brian G Feagan, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2011
Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's diseaseDouglas L Nguyen, William J Sandborn, Edward V Loftus, et al.
Pageof 48

Showing results (291-300 of 471) with videos related to

Sort By:
Pageof 48
Crohn'S & Colitis 360|August 28, 2023
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE StudiesWilliam J Sandborn, Jingjing Chen, Krisztina Kisfalvi, et al.
Gastroenterology|December 31, 2003
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patientsJean-Frederic Colombel, Edward V Loftus, William J Tremaine, et al.
Inflammatory Bowel Diseases|October 19, 2016
Increased Rates of Clostridium difficile Infection and Poor Outcomes in Patients with IBD with CytomegalovirusJeffrey D McCurdy, Felicity T Enders, Sahil Khanna, et al.
The American Journal of Gastroenterology|May 5, 2026
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE StudyEdward V Loftus, Namita Joshi, Bruce E Sands, et al.
Gut|December 15, 2016
Development of a Microscopic Colitis Disease Activity Index: a prospective cohort studyThomas G Cotter, Moritz Binder, Edward V Loftus, et al.
The American Journal of Gastroenterology|July 24, 2002
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitisElena Ricart, William R Taylor, Edward V Loftus, et al.
Journal of Crohn'S & Colitis|October 22, 2022
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's DiseaseRishika Chugh, Manuel B Braga-Neto, Thomas W Fredrick, et al.
The American Journal of Gastroenterology|October 16, 2008
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trialEdward V Loftus, Brian G Feagan, Jean-Frédéric Colombel, et al.
Journal of Crohn'S & Colitis|April 22, 2021
Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical TrialsJulian Panés, Séverine Vermeire, Marla C Dubinsky, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 14, 2011
Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's diseaseDouglas L Nguyen, William J Sandborn, Edward V Loftus, et al.
Pageof 48